Background/Aims: Pain in patients with chronic idiopathic axonal polyneuropathy (CIAP) has never been studied in detail. The aim of the study was to investigate the pain experienced by patients with CIAP, and to determine whether pain is associated with health-related quality of life (HRQoL). Methods: The McGill Pain Questionnaire (MPQ) and the RAND-36 were used in a cross-sectional study. Results: Sixty-three of 91 patients with CIAP reported experiencing pain, describing it as nagging (56%) and annoying (52%). Of these patients, 27 were classified in a subgroup with neuropathic pain (median VAS = 33 mm), 25 in a subgroup with non-neuropathic pain (median VAS = 34 mm), and 11 in a mixed-pain subgroup (median VAS = 25 mm). Non-neuropathic pain was as common and as painful as neuropathic pain. Pain was strongly associated with the physical functioning domain of the RAND-36 in patients in the mixed pain subgroup (r = –0.71, p < 0.05). Conclusion: Neuropathic and non-neuropathic pain syndromes should be distinguished in patients with CIAP who experience pain, to enable appropriate tailoring of treatment.

Keywords:
Neuropathic pain, Chronic idiopathic axonal polyneuropathy, McGill pain questionnaire
1.
McLeod JG, Tuck RR, Pollard JD, Cameron J, Walsh JC: Chronic polyneuropathy of undetermined cause. J Neurol Neurosurg Psychiatry 1984;47:530–535.
2.
Notermans NC, Wokke JHJ, Franssen H, van der Graaf Y, Vermeulen M, van den Berg LH, Bar PR, Jennekens FG: Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry 1993;56:1066–1071.
3.
Hughes RAC, Umapathi T, Gray IA, Gregson NA, Noori M, Pannala AS, Proteggente A, Swan AV: A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004;127:1723–1730.
4.
Helme RD, Gibson SJ: The epidemiology of pain in elderly people. Clin Geriatr Med 2001;17:417–431.
5.
Masson EA, Hunt L, Gem JM, Boulton AJM: A novel approach to the diagnosis and assessment of symptomatic diabetic neuropathy. Pain 1989;38:25–28.
6.
Boureau F, Doubrère JF, Luu M: Study of verbal description in neuropathic pain. Pain 1990;42:145–152.
7.
Dworkin RH: An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002;18:343–349.
8.
Jensen MP: Review of measures of neuropathic pain. Curr Pain Headache Rep 2006;10:159–166.
9.
Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, Scholz J, Tölle TR, Wittchen HU, Jensen TS: Using screening tools to identify neuropathic pain. Pain 2007;127:199–203.
10.
Galer BS, Jensen MP: Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997;48:332–338.
11.
Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29–36.
12.
Jensen MP, Chodroff MJ, Dworkin RH: The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68:1178–1182.
13.
Melzack R: The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277–299.
14.
Dudgeon BJ, Ehde DM, Cardenas DD, Engel JM, Hoffman AJ, Jensen MP: Describing pain with physical disability: narrative interviews and the McGill Pain Questionnaire. Arch Phys Med Rehabil 2005;86:109–115.
15.
van der Kloot WA, Oostendorp RAB, Van der Meij J, Van der Heuvel J: The Dutch version of the McGill pain questionnaire: a reliable pain questionnaire. Ned Tijdschr Geneesk 1995;139:669–673.
16.
van der Kloot WA, Vertommen H: De MPQ-DLV, een standaard nederlandstalige versie van de McGill Pain Questionnaire: Achtergronden en handleiding. Lisse, Swets & Zeitlinger, 1989.
17.
Verkes RJ, van der Kloot WA, van der Meij J: The perceived structure of 176 pain descriptive words. Pain 1989;38:219–229.
18.
Ware JE Jr, Sherbourne CD: The MOS-36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–483.
19.
van der Zee KI, Sanderman R: Het meten van de algemene gezondheidstoestand met de RAND-36. Een handleiding. Groningen, Noordelijk Centrum voor Gezondheidsvraagstukken, 1993.
20.
van der Zee KI, Sanderman R, Heyink J: De psychometrische kwaliteiten van de MOS 36-item Short Form Health Survey (SF-36) in een Nederlandse populatie. T Soc Gezondheidsz 1993;71:183–191.
21.
Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977;33:159–174.
22.
Streiner DL, Norman GR: Health Measurement Scales: A Practical Guide to Their Development and Use. New York, Oxford University Press, 1995.
23.
Collins SL, Moore RA, McQuay HJ: The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 1997;72:95–97.
24.
Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277–284.
25.
Learner J, Goodman NW: Descriptions of correlation. Lancet 1996;348:199–200.
26.
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J: Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630–1635.
27.
Dworkin RH, Jensen MP, Gammaitoni AR, Olaleye DO, Galer BS: Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain 2007;8:118–126.
28.
Otto M, Bach FW, Jensen TS, Sindrup SH: Health-related quality of life and its predictive role for analgesic effect in patients with painful polyneuropathy. Eur J Pain 2007;11:572–578.
29.
Otto M, Bak S, Bach FW, Jensen TS, Sindrup SH: Pain phenomena and possible mechanisms in patients with painful polyneuropathy. Pain 2003;101:187–192.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.